Nachrichten zur AstraZeneca PLC Aktie

AstraZeneca And Ionis Pharma Rocked By Heart Disease Fail: Why You Shouldnt Panic

…

AstraZenecas Wainua failure hurts credibility more than valuation, Jefferies warns

The damage to AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) from Wainuas trial failure is less about the numbers than about a dent…

AstraZenecas Wainua failure hurts credibility more than valuation, Jefferies warns

The damage to AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) from Wainuas trial failure is less about the numbers than about a dent…

AstraZenecas Rare Drug Trial Failure Sends Shares Plunging

AstraZeneca Plcs shares dropped more than 10% after a trial of a new heart drug failed to help prevent heart…

AstraZenecas Stock Drops on Wainuas Setback in ATTR-CM Study

AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into…

Opening Bell: Wall Street startet im Plus; AstraZeneca, PepsiCo, Fuelcell Energy, Arista Networks. ...

Trotz zunehmender militärischer Auseinandersetzungen zwischen den USA und dem Iran werden die US-Aktienmärkte am Donnerstag moderat im Plus erwartet. Eine…

AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse

A late-stage clinical trial failed to miss its primary endpoint, U.K.s laregst drugmaker said Thursday.…

Stocks making the biggest moves premarket: AstraZeneca, PepsiCo, Salesforce, Levi & more

These are the stocks posting the largest moves in the premarket.…

FTSE 100 dragged lower by AstraZeneca

The FTSE 100 fell on Thursday as AstraZeneca dragged the index lower after releasing disappointing trial results for a cardiovascular drug.…

AstraZeneca sees stock market value slump by more than £20bn after drug setback

The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.…

Astrazeneca-Kandidat Wainua verfehlt Ziel in klinischer Studie - Aktie sackt ab

LONDON (dpa-AFX) - Der Astrazeneca-Hoffnungsträger Wainua hat in einer klinischen Studie enttäuscht. In der Phase-3-Studie verfehlte…

AstraZenecas £19bn blow as Wainua heart drug fails key late-stage trial

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 9.55% in early trading, wiping £19 billion from the companys valuation, after its Wainua drug…

AstraZenecas £19bn blow as Wainua heart drug fails key late-stage trial

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 9.55% in early trading, wiping £19 billion from the companys valuation, after its Wainua drug…

FTSE 100 Live: London index hit by AstraZeneca failure, Computacenter and Playtech soar

FTSE 100 down 61 points to  AstraZeneca tumbles after clinical trial failure Computacenter and Playtech soar after trading updates 10.26am: Playtech…

FTSE 100 Live: AstraZeneca drags while Computacenter soars, US AI stocks gain

FTSE 100 down 39 points to 10,450 AstraZeneca tumbles after clinical trial failure Computacenter and Playtech soar after trading updates  2.42pm:…

FTSE 100 Live: Index opens lower after AstraZeneca trial failure, Computacenter surges

8.14am: AstraZeneca drags FTSE into red The FTSE 100 opened higher in the first two minutes of trading but has…

FTSE 100 Live: AstraZeneca exerts big drag, Computacenter and Playtech soar

FTSE 100 down 49 points to 10,440 AstraZeneca tumbles after clinical trial failure Computacenter and Playtech soar after trading updates  2.29pm:…

FTSE 100 Live: London index stands alone in red after AstraZeneca trial failure

9.31am: European markets rebound, apart from the FTSE After an hour and a half of trading, European markets are broadly higher,…

AstraZeneca Aktie: Kaufchance - trotz gesenktem Kursziel!

London (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von HSBC:Die HSBC habe das Kursziel für die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455,…

Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer…

AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation Transcript

…

Citi keeps AstraZeneca on buy ahead of second-quarter results

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has been kept on a buy rating by Citi, which pointed to a run of late-stage drug…

1,77 Mrd. USD für neue Pipelines: Was AstraZenecas Asien-Deals für Anleger bedeuten

Der Konzern investiert bis zu 1,77 Mrd. USD in eine neue Lizenzvereinbarung mit CSPC für Nierenerkrankungen. Eine klinische Kooperation…

AstraZenecas Enhertu Wins EU Nod for HER2-Positive Solid Tumors

AZNs Enhertu wins its sixth EU indication with a tumor-agnostic approval. Datroway moves closer to a first-line TNBC EU nod…

Jefferies names AstraZeneca a top pick ahead of pivotal heart drug readout

Jefferies has reiterated its buy rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) and named the drugmaker a Franchise Pick, framing an approaching...…

ANALYSE-FLASH: Jefferies belässt Astrazeneca auf 'Buy' - Ziel 18000 Pence

NEW YORK (dpa-AFX Broker) - Das Analysehaus Jefferies hat die Einstufung für Astrazeneca mit einem…

Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note

In the most recent trading session, Astrazeneca (AZN) closed at $185.68, indicating a +1.45% shift from the previous trading day.…

The Zacks Analyst Blog Highlights Applied Materials, GE, AstraZeneca, Team and Applied Energetics

Applied Materials, GE Aerospace and AstraZeneca headline Zacks research picks, backed by strong industry outperformance and key growth drivers.…

AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?

AZN shares fell after a camizestrant setback, but blockbuster drugs, oncology growth and a deep pipeline support long-term targets.…

Top Stock Reports for Applied Materials, GE & AstraZeneca

Todays Research Daily features new research reports on 16 major stocks, including Applied Materials, Inc. (AMAT), GE Aerospace (GE) and…

AstraZeneca says AI is raising its odds where most drugs fail

The most expensive product in modern business is the one that never ships. Nowhere is that more true than in…

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know

In the most recent trading session, Astrazeneca (AZN) closed at $182.28, indicating a +1.86% shift from the previous trading day.…

Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal

GSKs record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmakers rebuild of its cancer drug business…

JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?

J&Js diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.…

AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout the research…

AstraZeneca Broadens US Growth Push

AstraZeneca CFO Aradhana Sarin discusses how the pharmaceutical company is broadening its US shareholder base and plans to generate $80…

AstraZeneca CEO: AI is affecting every part of our company

AstraZeneca CEO Pascal Soriot joins CNBC’s Angelica Peebles to discuss the most promising drugs in AstraZeneca’s pipeline. He says the…

Can AstraZenecas Expanding Cancer Portfolio Sustain Momentum?

AstraZenecas oncology sales hit $6.8B in first-quarter 2026, fueled by key cancer drugs. New launches and late-stage pipeline assets support…

Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions

Deutsche Bank has kept its sell rating and 11,500p price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals…

ANALYSE-FLASH: Barclays belässt Astrazeneca auf 'Overweight' - Ziel 16500 Pence

LONDON (dpa-AFX Broker) - Die britische Investmentbank Barclays hat die Einstufung für Astrazeneca auf "Overweight"…

ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do

This years American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical companies, with no…

Admission of Further Securities to Trading

1 June 2026Notification of Admission of Further Securities to Trading (PRM 1.6.4R)The following notification is made in accordance with The…

US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial

Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of…

US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial

Citi sees the risk-reward balance as favourable for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) ahead of headline results from a pivotal trial of…

AIM movers: Potential farm out partners for Borders & Southern and CelLBxHealth deal with AstraZeneca

Parsortix liquid biopsy system developer CelLBxHealth (LON: CLBX) has entered an agreement with AstraZeneca which makes the AIM company a…

CelLBxHealth shares soar after inking agreement with AstraZeneca

AIM-listed CelLBxHealth has secured a Master Services Agreement with AstraZeneca, giving the circulating tumour cell specialist qualified service provider status…

AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins

…

AZN, Daiichis Enhertu Gets FDA Nod for Two New Breast Cancer Settings

AstraZeneca and Daiichi win FDA approval for Enhertu in two new HER2-positive early breast cancer treatment settings.…

AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy

AZNs Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.…

AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment Enhertu

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured US approval for Baxfendy, the first in a new class of blood pressure medication…